F11 - Syncing Data and Care: Using CGM to Improve Cardiometabolic Kidney Care

Friday, August 8, 2025

11:30 AM – 12:15 PM MT

CE/CME Hours: .75 CE

Pharmacology Hours: .50 CE

Primary Presenter(s)

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP (she/her/hers)

Professor, Pharmacy Practice, PGY2 Ambulatory Care Residency Program Director, Clinical Pharmacist
Midwestern University and Northwestern Medicine
Chicago, Illinois

Disclosure(s): Abbott: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Terminated, April 21, 2023)

Select GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated cardiovascular (CV) benefits in both primary and secondary prevention populations and are recommended in multiple guidelines for CV risk reduction, chronic kidney disease (CKD) and heart failure (HF) in people with type 2 diabetes (T2D). Despite this, uptake of GLP-1 receptor agonists and SGLT2 inhibitors in clinical practice has been lagging. This session provides examples of how to use continuous glucose monitoring to deprescribe insulin and other antihyperglycemic therapies and optimize those therapies with cardio-kidney-metabolic (CKM) benefit.

Disclosure(s):

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP: Abbott: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Terminated, April 21, 2023)